{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-154338","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.841287+00:00","generated_at":"2026-06-14T14:38:37.998057+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"4D Molecular Therapeutics announces shareholder vote results; all director nominees elected and auditor ratified","bullets":["At May 23 annual meeting, 27,970,603 of 33,235,726 outstanding shares voted, representing 84.1% quorum.","Class III directors elected: Nancy Miller-Rich (25,544,878 for, 648,302 withheld), John F. Milligan (26,011,514 for, 181,666 withheld), Shawn Cline Tomasello (20,935,207 for, 5,257,973 withheld).","Ratification of PricewaterhouseCoopers LLP as auditor for FY2023 passed with 27,957,650 for, 6,435 against, 6,518 abstain.","Broker non-votes on director election totaled 1,777,423 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-154338","json":"https://secwatch.observer/filing/0001193125-23-154338.json","markdown":"https://secwatch.observer/filing/0001193125-23-154338.md","text":"https://secwatch.observer/filing/0001193125-23-154338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523154338/0001193125-23-154338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523154338/d350381d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:38:37.998057+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3084e2936bf13aab5df15ed8b033082803cc58ce","claim":"4D Molecular Therapeutics, Inc. shareholders approved Election of Class III director nominees at the 2023-05-23 meeting.","evidence_excerpt":"Proposal 1. The Company’s stockholders elected by a majority of votes cast the Class III director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523154338/0001193125-23-154338-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-23"}],"fact_type":"shareholder_vote"},{"claim_id":"650eec632d9dbc38d7f593a4d6364363e7cab1b7","claim":"4D Molecular Therapeutics, Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-23 meeting.","evidence_excerpt":"Proposal 2. The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523154338/0001193125-23-154338-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-23"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}